Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

被引：0
|
作者：
Bissonnette, R. [1 ]
Iversen, L. [2 ]
Sofen, H. [3 ]
Griffiths, C. E. M. [4 ,5 ]
Foley, P. [6 ]
Romiti, R. [7 ]
Bachinsky, M. [8 ]
Rottinghaus, S. T. [8 ]
Tan, H. [8 ]
Proulx, J. [8 ]
Valdez, H. [9 ]
Gupta, P. [8 ]
Mallbris, L. [10 ]
Wolk, R. [8 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA USA
[4] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[5] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[6] Univ Melbourne, Skin & Canc Fdn Inc, Carlton, Vic 3053, Australia
[7] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Inc, New York, NY USA
[10] Pfizer Inc, Collegeville, PA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [31] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
    Blauvelt, Andrew
    Reich, Kristian
    Drew, Janice
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [32] Efficacy and safety of picankibart in moderate-to-severe plaque psoriasis: a randomized, double-blind, Phase 3 CLEAR-1 trial
    Shi, Yuling
    Qin, Lanying
    Li, Yumei
    Cui, Yong
    Zhang, Shifa
    Chen, Mingxia
    Cai, Chenghang
    Qian, Lei
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [33] Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
    Ma, Guangli
    Xie, Rujia
    Strober, Bruce
    Langley, Richard
    Ito, Kaori
    Krishnaswami, Sriram
    Wolk, Robert
    Valdez, Hernan
    Rottinghaus, Scott
    Tallman, Anna
    Gupta, Pankaj
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 587 - 596
  • [34] Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
    Kuo, C. -M.
    Tung, T. -H.
    Wang, S. -H.
    Chi, C. -C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 355 - 362
  • [35] Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
    Papp, K.
    Crowley, J.
    Ortonne, J. -P.
    Leu, J.
    Okun, M.
    Gupta, S. R.
    Gu, Y.
    Langley, R. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (02) : 434 - 441
  • [36] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Beck, Lisa A.
    Anderson, Jaclyn K.
    Hu, Xiaofei
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB294 - AB294
  • [37] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
    Frampton, James E.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 295 - 306
  • [38] Advances in the treatment of moderate-to-severe plaque psoriasis
    Herrier, Richard N.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 795 - 806
  • [39] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [40] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
12345